Published in Cancer Weekly, April 6th, 1998
In this trial, the primary endpoints of reduction in neutropenia-related infections and reduction in BMT-treatment-associated mortality were not met.
Carolyn M. Paradise, M.D., Cell Therapeutics, said the company believes that the results were affected by unusually aggressive treatment regimens clinicians were using with older patients (i.e., >50 years) who were...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.